Samenvatting: Incyte presenteert Fase 1/2 multidosisgegevens voor VGA039 (latarcibart) tijdens ISTH 2026, die aanzienlijke vermindering van bloedingen aantonen bij patiënten met alle types van de ziekte van Von Willebrand
Tuesday, July 14, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Incyte has announced positive results from a Phase 1/2 study of VGA039 (latarcibart), a monoclonal antibody targeting protein S, for patients with Von Willebrand disease. The study involved 16 patients and demonstrated a significant reduction in bleeding episodes. This data was presented during the ISTH 2026 conference.
Price reaction · baseline $114.23 (2026-07-13 close) · hit pre-market · 2 other INCY headline(s) in the window, move may be shared
day 0 close · peak
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Significant reduction in bleeding observed in patients.
Data presented from a Phase 1/2 study indicates effectiveness.
VGA039 (latarcibart) shows promise for treating Von Willebrand disease.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+44%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
INCB013739
Phase 2 · Type 2 Diabetes
Full Press Release Details
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) maakte vandaag de gegevens bekend over de volledige veiligheid en doeltreffendheid bij alle patiënten (n=16) die deelnamen aan de Fase 1/2 multidosis-studie van VGA039 (latarcibart), een nieuw, op proteïne S gericht, monoklonaal antilichaam in onderzoeksfase voor patiënten met de ziekte van von Willebrand (VWD). Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden
Frequently Asked Questions
What is VGA039 (latarcibart)?
VGA039 (latarcibart) is a monoclonal antibody targeting protein S for treating Von Willebrand disease.
What were the results of the Phase 1/2 study?
The study showed a significant reduction in bleeding episodes among the 16 patients.
Where was the data presented?
The data was presented at the ISTH 2026 conference.
How many patients participated in the study?
A total of 16 patients participated in the Phase 1/2 study.